Advertisement
RAPT Therapeutics Inc. (RAPT)
NASDAQ: RAPT
· Real-Time Price · USD
0.92
-0.00 (-0.12%)
At close: Apr 29, 2025, 9:41 AM
-0.12% (1D)
| Bid | 0.64 |
| Market Cap | 121.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -129.87M |
| EPS (ttm) | -3.19 |
| PE Ratio (ttm) | -0.29 |
| Forward PE | -1.29 |
| Analyst | Hold |
| Ask | 1.18 |
| Volume | 37,540 |
| Avg. Volume (20D) | 732,963 |
| Open | 0.91 |
| Previous Close | 0.92 |
| Day's Range | 0.90 - 0.96 |
| 52-Week Range | 0.75 - 8.58 |
| Beta | -0.29 |
About RAPT
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead onco...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 31, 2019
Employees 68
Stock Exchange NASDAQ
Ticker Symbol RAPT
Website https://www.rapt.com
Advertisement
Analyst Forecast
According to 7 analyst ratings, the average rating for RAPT stock is "Hold." The 12-month stock price forecast is $4, which is an increase of 336.11% from the latest price.
Stock Forecasts4 months ago
+110.81%
RAPT Therapeutics shares are trading higher after ...
Unlock content with
Pro Subscription
5 months ago
-39.45%
RAPT Therapeutics shares are trading lower after the company terminated its Zelnecirnon program following an FDA clinical hold due to a severe adverse event involving liver injury.
